The DOI matches its Crossref record; 42 of the 43 references it cites were found in a registry or an index.
Dexamethasone in Hospitalized Patients with Covid-19
Open accessPublished version of a preprint
Abstract
BACKGROUND: Coronavirus disease 2019 (Covid-19) is associated with diffuse lung damage. Glucocorticoids may modulate inflammation-mediated lung injury and thereby reduce progression to respiratory failure and death. METHODS: In this controlled, open-label trial comparing a range of possible treatments in patients who were hospitalized with Covid-19, we randomly assigned patients to receive oral or intravenous dexamethasone (at a dose of 6 mg once daily) for up to 10 days or to receive usual care alone. The primary outcome was 28-day mortality. Here, we report the final results of this assessment. RESULTS: A total of 2104 patients were assigned to receive dexamethasone and 4321 to receive usual care. Overall, 482 patients (22.9%) in the dexamethasone group and 1110 patients (25.7%) in the usual care group died within 28 days after randomization (age-adjusted rate ratio, 0.83; 95% confidence interval [CI], 0.75 to 0.93; P<0.001). The proportional and absolute between-group differences in mortality varied considerably according to the level of respiratory support that the patients were receiving at the time of randomization. In the dexamethasone group, the incidence of death was lower than that in the usual care group among patients receiving invasive mechanical ventilation (29.3% vs. 41.4%; rate ratio, 0.64; 95% CI, 0.51 to 0.81) and among those receiving oxygen without invasive mechanical ventilation (23.3% vs. 26.2%; rate ratio, 0.82; 95% CI, 0.72 to 0.94) but not among those who were receiving no respiratory support at randomization (17.8% vs. 14.0%; rate ratio, 1.19; 95% CI, 0.92 to 1.55). CONCLUSIONS: In patients hospitalized with Covid-19, the use of dexamethasone resulted in lower 28-day mortality among those who were receiving either invasive mechanical ventilation or oxygen alone at randomization but not among those receiving no respiratory support. (Funded by the Medical Research Council and National Institute for Health Research and others; RECOVERY ClinicalTrials.gov number, NCT04381936; ISRCTN number, 50189673.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“reports of hemophagocytosis and elevated cytokine levels — as well as beneficial effects of immunosuppressant agents — in affected patients, particularly those who are the most severely ill, suggest that cytokine storm may contribute to the pathogenesis of Covid-19.87,88”
From Cytokine storm (2020) · cites this paper as [88]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Until the release of the RECOVERY trial,66 patients with severe COVID-19 were not routinely treated with GC agonists such as dexamethasone.”
From Cystatin C is glucocorticoid responsive, directs recruitment of Trem2+ macrophages, and predicts failure of cancer immunotherapy (2023) · cites this paper as [66]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“In addition, dexamethasone reduces the death rate of patients with severe COVID-19 (370).”
From IL-6 in inflammation, autoimmunity and cancer (2021) · cites this paper as [370]
In the citing paper
“These studies were, however, restricted to only publications up to August and October 2020—which is not representative of the current landscape of covid-19 research and which does not include the majority of evidence being currently used to guide covid-19 care, including critical trials of the effects of corticosteroids and interleukin 6 receptor blockers.”
From Consistency of covid-19 trial preprints with published reports and impact for decision making: retrospective review (2022) · cites this paper as [2]
In the citing paper
“a recent randomized, controlled trial showing that dexamethasone reduces mortality among the most severe cases of Covid-19, characterized by elevated CRP levels and supplemental oxygen requirements, and potentially worsens outcomes in milder cases suggests that excessive, late-stage inflammation contributes to mortality.88”
From Cytokine storm (2020) · cites this paper as [88]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L., Fan, G., Xu, J., Gu, X., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30183-5 · Cited by 48,884
A novel coronavirus from patients with pneumonia in China, 2019
Zhu, N., Zhang, D., Wang, W., Li, X., Yang, B., Song, J., Zhao, X., Huang, B., Shi, W., Lu, R., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2001017 · Cited by 28,244
Zhou, F., Yu, T., Du, R., Fan, G., Liu, Y., Liu, Z., Xiang, J., Wang, Y., Song, B., Gu, X., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30566-3 · Cited by 27,263
Chen, N., Zhou, M., Dong, X., Qu, J., Gong, F., Han, Y., Qiu, Y., Wang, J., Liu, Y., Wei, Y., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30211-7 · Cited by 21,415
Wang, D., Hu, B., Hu, C., Zhu, F., Liu, X., Zhang, J., Wang, B., Xiang, H., Cheng, Z., Xiong, Y., et al. (2020) · JAMA · doi:10.1001/jama.2020.1585 · Cited by 20,148
Remdesivir for the Treatment of Covid-19 — Final Report
Beigel, J. H., Tomashek, K. M., Dodd, L. E., Mehta, A. K., Zingman, B. S., Kalil, A. C., Hohmann, E., Chu, H. Y., Luetkemeyer, A., Kline, S., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2007764 · Cited by 7,267
Virological assessment of hospitalized patients with COVID-2019
Wölfel, R., Corman, V. M., Guggemos, W., Seilmaier, M., Zange, S., Müller, M. A., Niemeyer, D., Jones, T. C., Vollmar, P., Rothe, C., et al. (2020) · Nature · doi:10.1038/s41586-020-2196-x · Cited by 6,661
Ruan, Q., Yang, K., Wang, W., Jiang, L., & Song, J. (2020) · Intensive Care Medicine · doi:10.1007/s00134-020-05991-x · Cited by 4,898
Temporal dynamics in viral shedding and transmissibility of COVID-19
He, X., Lau, E. H. Y., Wu, P., Deng, X., Wang, J., Hao, X., Lau, Y. C., Wong, J. Y., Guan, Y., Tan, X., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0869-5 · Cited by 4,300
Estimates of the severity of coronavirus disease 2019: a model-based analysis
Verity, R., Okell, L. C., Dorigatti, I., Winskill, P., Whittaker, C., Imai, N., Cuomo-Dannenburg, G., Thompson, H., Walker, P. G. T., Fu, H., et al. (2020) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30243-7 · Cited by 3,660
Research works printed but not linked: 2
- Corral-Gudino L Bahamonde A Arnaiz-Revillas F et al. GLUCOCOVID: a controlled trial of methylprednisolone in adults hospitalized with COVID-19 pneumonia. June 18 2020 (https://www.medrxiv.org/content/10.1101/2020.06.17.20133579v1). preprint. · DOI
- Siemieniuk R, Rochwerg B, Agoritsas T, et al. A living WHO guideline on drugs for Covid-19. BMJ 2020;370:m3379-m3379.32887691
Cited by
Sorted by citations
Remdesivir for the Treatment of Covid-19 — Final Report
Beigel, J. H., Tomashek, K. M., Dodd, L. E., Mehta, A. K., Zingman, B. S., Kalil, A. C., Hohmann, E., Chu, H. Y., Luetkemeyer, A., Kline, S., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2007764 · Cited by 7,267
Characteristics of SARS-CoV-2 and COVID-19
Hu, B., Guo, H., Zhou, P., & Shi, Z.-L. (2021) · Nature Reviews Microbiology · doi:10.1038/s41579-020-00459-7 · Cited by 5,291
RETRACTED: 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study
Huang, C., Huang, L., Wang, Y., Li, X., Ren, L., Gu, X., Kang, L., Guo, L., Liu, M., Zhou, X., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32656-8 · Cited by 4,084
RetractedFajgenbaum, D. C., & June, C. H. (2020) · New England Journal of Medicine · doi:10.1056/nejmra2026131 · Cited by 3,196
Features, Evaluation and Treatment Coronavirus (COVID-19)
Cascella, M., Rajnik, M., Cuomo, A., Dulebohn, S. C., & Napoli, R. D. (2020) · StatPearls · Cited by 3,351
Repurposed Antiviral Drugs for Covid-19 — Interim WHO Solidarity Trial Results
Pan, H., Peto, R., Karim, Q. A., Alejandria, M. M., Henao-Restrepo, A. M., Garcia, P. J., Kiény, M.-P., Malekzadeh, R., Murthy, S., Préziosi, M., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2023184 · Cited by 2,748
An inflammatory cytokine signature predicts COVID-19 severity and survival
Del Valle, D. M., Kim-Schulze, S., Huang, H.-H., Beckmann, N. D., Nirenberg, S., Wang, B., Lavin, Y., Swartz, T. H., Madduri, D., Stock, A., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-1051-9 · Cited by 2,605
The WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group, Sterne, J. A. C., Murthy, S., Diaz, J. V., Slutsky, A. S., Villar, J., Angus, D. C., Annane, D., Azevedo, L. C. P., Berwanger, O., et al. (2020) · JAMA · doi:10.1001/jama.2020.17023 · Cited by 2,257
Self-citationInterleukin-6 receptor antagonists in critically ill patients with Covid-19.
The REMAP-CAP Investigators (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2100433 · Cited by 1,962
Abani, O., Abbas, A., Abbas, F., Abbas, M., Abbasi, S., Abbass, H., Abbott, A., Abdallah, N., Abdelaziz, A., Abdelfattah, M., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00676-0 · Cited by 1,983
Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19
Kalil, A. C., Patterson, T. F., Mehta, A. K., Tomashek, K. M., Wolfe, C. R., Ghazaryan, V., Marconi, V. C., Ruiz-Palacios, G. M., Hsieh, L. L., Kline, S., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2031994 · Cited by 1,840
REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19
Weinreich, D. M., Sivapalasingam, S., Norton, T., Ali, S., Gao, H., Bhore, R., Musser, B. J., Soo, Y., Rofail, D., Im, J., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2035002 · Cited by 1,642
Severe COVID-19 Is Marked by a Dysregulated Myeloid Cell Compartment
Schulte-Schrepping, J., Reusch, N., Paclik, D., Baßler, K., Schlickeiser, S., Zhang, B., Krämer, B., Krammer, T., Brumhard, S., Bonaguro, L., et al. (2020) · Cell · doi:10.1016/j.cell.2020.08.001 · Cited by 1,461
IL-6 in inflammation, autoimmunity and cancer
Hirano, T. (2021) · International Immunology · doi:10.1093/intimm/dxaa078 · Cited by 1,453
Genetic mechanisms of critical illness in COVID-19
The GenOMICC Investigators, Pairo‐Castineira, E., The ISARIC4C Investigators, Initiative, T. C.-1. H. G., 23andMe Investigators, BRACOVID Investigators, Gen-COVID Investigators, Clohisey, S., Klarić, L., Bretherick, A. D., et al. (2020) · Nature · doi:10.1038/s41586-020-03065-y · Cited by 1,356
Efficacy of Tocilizumab in Patients Hospitalized with Covid-19
Stone, J. H., Frigault, M. J., Serling-Boyd, N. J., Fernandes, A. D., Harvey, L., Foulkes, A. S., Horick, N. K., Healy, B. C., Shah, R., Bensaci, A. M., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2028836 · Cited by 1,362
Tomazini, B. M., Maia, I. S., Cavalcanti, A. B., Berwanger, O., Rosa, R. G., Veiga, V. C., Avezum, A., Lopes, R. D., Bueno, F. R., Silva, M. V. A. O., et al. (2020) · JAMA · doi:10.1001/jama.2020.17021 · Cited by 1,241
Gandhi, R. T., Lynch, J. B., & del Río, C. (2020) · New England Journal of Medicine · doi:10.1056/nejmcp2009249 · Cited by 1,341
Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia
Salama, C., Han, J., Yau, L., Reiss, W. G., Krämer, B., Neidhart, J. D., Criner, G. J., Kaplan‐Lewis, E., Baden, R. P., Pandit, L. M., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2030340 · Cited by 1,306
SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19
Chen, P., Nirula, A., Heller, B., Gottlieb, R. L., Boscia, J., Morris, J., Huhn, G., Cardona, J., Mocherla, B., Stosor, V., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2029849 · Cited by 1,282
The T cell immune response against SARS-CoV-2
Moss, P. A. H. (2022) · Nature Immunology · doi:10.1038/s41590-021-01122-w · Cited by 1,243
Spinner, C. D., Gottlieb, R., Criner, G. J., Arribas, J. R., Cattelan, A. M., Soriano, À., Ogbuagu, O. E., Malhotra, P., Mullane, K. M., Castagna, A., et al. (2020) · JAMA · doi:10.1001/jama.2020.16349 · Cited by 1,234
Popkin, B. M., Du, S., Green, W. D., Beck, M. A., Algaith, T., Herbst, C. H., Alsukait, R. F., Alluhidan, M., Alazemi, N., & Shekar, M. (2020) · Obesity Reviews · doi:10.1111/obr.13128 · Cited by 1,150
Acute respiratory distress syndrome
Meyer, N. J., Gattinoni, L., & Calfee, C. S. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00439-6 · Cited by 1,242
Xu, S., Ilyas, I., Little, P. J., Li, H., Kamato, D., Zheng, X., Luo, S., Li, Z., Liu, P., Han, J., et al. (2021) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000096 · Cited by 1,205
Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia
Rosas, I. O., Bräu, N., Waters, M., Go, R. C., Hunter, B. D., Bhagani, S., Skiest, D. J., Aziz, M. S., Cooper, N., Douglas, I. S., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2028700 · Cited by 1,141
A living WHO guideline on drugs for covid-19 (2020-2023)
Agarwal, A., Hunt, B. J., Stegemann, M., Rochwerg, B., Lamontagne, F., Siemieniuk, R. A., Agoritsas, T., Askie, L., Lytvyn, L., Leo, Y.-S., et al. (2020) · BMJ · doi:10.1136/bmj.m3379 · Cited by 1,041
RECOVERY Collaborative Group (2021) · White Rose Research Online (University of Leeds, The University of Sheffield, University of York) · doi:10.17863/cam.70428 · Cited by 1,071
Acute respiratory distress syndrome: causes, pathophysiology, and phenotypes
Bos, L. D. J., & Ware, L. B. (2022) · The Lancet · doi:10.1016/s0140-6736(22)01485-4 · Cited by 1,091
COVID-19 and diabetes mellitus: from pathophysiology to clinical management
Lim, S. K., Bae, J. H., Kwon, H., & Nauck, M. A. (2020) · Nature Reviews Endocrinology · doi:10.1038/s41574-020-00435-4 · Cited by 1,061
Lamers, M. M., & Haagmans, B. L. (2022) · Nature Reviews Microbiology · doi:10.1038/s41579-022-00713-0 · Cited by 1,066
International consensus statement on allergy and rhinology: rhinosinusitis 2021
Orlandi, R. R., Kingdom, T. T., Smith, T. L., Bleier, B. S., DeConde, A. S., Luong, A., Poetker, D. M., Soler, Z. M., Welch, K. C., Wise, S. K., et al. (2020) · International Forum of Allergy & Rhinology · doi:10.1002/alr.22741 · Cited by 1,084
COVID-19 is, in the end, an endothelial disease
Libby, P., & Lüscher, T. F. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehaa623 · Cited by 989
Koehler, P. A., Bassetti, M., Chakrabarti, A., Chen, S. C. ‐., Colombo, A. L., Hoenigl, M., Климко, Н. Н., Lass‐Flörl, C., Oladele, R. O., Vinh, D. C., et al. (2020) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30847-1 · Cited by 956
A dynamic COVID-19 immune signature includes associations with poor prognosis
Laing, A. G., Lorenc, A., del Molino del Barrio, I., Das, A., Fish, M., Monin, L., Muñoz-Ruiz, M., McKenzie, D. R., Hayday, T. S., Francos-Quijorna, I., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-1038-6 · Cited by 946
Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19
The REMAP-CAP, A.-4. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2103417 · Cited by 944
COVID-ICU Group on behalf of the REVA Network and the COVID-ICU Investigators (2020) · Intensive Care Medicine · doi:10.1007/s00134-020-06294-x · Cited by 913
A Randomized Trial of Convalescent Plasma in Covid-19 Severe Pneumonia
Simonovich, V., Pratx, L. D. B., Scibona, P., Beruto, V., Vallone, M. G., Vázquez, C., Savoy, N., Giunta, D. H., Pérez, L. G., Sanchez, M. D. L., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2031304 · Cited by 905
6-month consequences of COVID-19 in patients discharged from hospital: a cohort study
Huang, C., Huang, L., Wang, Y., Li, X., Ren, L., Gu, X., Kang, L., Guo, L., Liu, M., Zhou, X., et al. (2023) · The Lancet · doi:10.1016/s0140-6736(23)00810-3 · Cited by 916
Effect of Hydrocortisone on Mortality and Organ Support in Patients With Severe COVID-19
Angus, D. C., Derde, L. P. G., Al-Beidh, F., Annane, D., Arabi, Y. M., Beane, A., van Bentum-Puijk, W., Berry, L. R., Bhimani, Z., Bonten, M. J. M., et al. (2020) · JAMA · doi:10.1001/jama.2020.17022 · Cited by 858
Leisman, D. E., Ronner, L., Pinotti, R., Taylor, M. D., Sinha, P., Calfee, C. S., Hirayama, A. V. V., Mastroianni, F., Turtle, C. J., Harhay, M. O., et al. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(20)30404-5 · Cited by 874
Drug treatments for covid-19: living systematic review and network meta-analysis
Siemieniuk, R. A., Bartoszko, J. J., Zeraatkar, D., Kum, E., Qasim, A., Díaz Martinez, J. P., Izcovich, A., Rochwerg, B., Lamontagne, F., Han, M. A., et al. (2020) · BMJ · doi:10.1136/bmj.m2980 · Cited by 846
The Lancet Commission on lessons for the future from the COVID-19 pandemic
Sachs, J. D., Karim, S. S. A., Aknin, L., Allen, J., Brosbøl, K., Colombo, F., Barron, G. C., Espinosa, M. F., Gaspar, V., Gaviria, A., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(22)01585-9 · Cited by 842
COVID-19 and multisystem inflammatory syndrome in children and adolescents
Jiang, L., Tang, K., Levin, M., Irfan, O., Morris, S. K., Wilson, K. M., Klein, J. D., & Bhutta, Z. A. (2020) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30651-4 · Cited by 848
Extrafollicular B cell responses correlate with neutralizing antibodies and morbidity in COVID-19
Woodruff, M. C., Ramonell, R. P., Nguyen, D. C., Cashman, K. S., Saini, A. S., Haddad, N. S., Ley, A. M., Kyu, S., Howell, J. C., Ozturk, T., et al. (2020) · Nature Immunology · doi:10.1038/s41590-020-00814-z · Cited by 791
Torres, A., Cillóniz, C., Niederman, M. S., Menéndez, R., Chalmers, J. D., Wunderink, R. G., & van der Poll, T. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-021-00259-0 · Cited by 904
COVID-19 and the human innate immune system
Schultze, J. L., & Aschenbrenner, A. C. (2021) · Cell · doi:10.1016/j.cell.2021.02.029 · Cited by 714
Comparative host-coronavirus protein interaction networks reveal pan-viral disease mechanisms
Gordon, D. E., Hiatt, J. B., Bouhaddou, M., Rezelj, V. V., Ulferts, S., Braberg, H., Jureka, A. S., Obernier, K., Guo, J. Z., Batra, J., et al. (2020) · Science · doi:10.1126/science.abe9403 · Cited by 747
Hermine, O., Mariette, X., Tharaux, P.-L., Resche-Rigon, M., Porcher, R., Ravaud, P., CORIMUNO-19 Collaborative Group, Bureau, S., Dougados, M., Tibi, A., et al. (2021) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2020.6820 · Cited by 734
Neutralizing monoclonal antibodies for treatment of COVID-19
Taylor, P. C., Adams, A. C., Hufford, M. M., de la Torre, I., Winthrop, K., & Gottlieb, R. L. (2021) · Nature Reviews Immunology · doi:10.1038/s41577-021-00542-x · Cited by 732
Castillo, M. E., Costa, L. M. E., Barrios, J. M. V., Alcala-Diaz, J. F., López‐Miranda, J., Bouillon, R., & Gómez, J. M. (2020) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2020.105751 · Cited by 758
Circuits between infected macrophages and T cells in SARS-CoV-2 pneumonia
Grant, R. A., Morales‐Nebreda, L., Markov, N. S., Swaminathan, S., Querrey, M., Rios-Guzman, E., Abbott, D. A., Donnelly, H. K., Donayre, A., Goldberg, I. A., et al. (2021) · Nature · doi:10.1038/s41586-020-03148-w · Cited by 718
Marconi, V. C., Ramanan, A. V., de Bono, S., Kartman, C. E., Krishnan, V., Liao, R., Piruzeli, M. L. B., Goldman, J. D., Alatorre-Alexander, J., Pellegrini, R. D. C., et al. (2021) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(21)00331-3 · Cited by 764
COVID-19 Neutralizing Antibodies Predict Disease Severity and Survival
García-Beltrán, W. F., Lam, E. C., Astudillo, M. G., Yang, D., Miller, T. E., Feldman, J. E., Hauser, B. M., Caradonna, T. M., Clayton, K., Nitido, A. D., et al. (2020) · Cell · doi:10.1016/j.cell.2020.12.015 · Cited by 708
Horby, P., Mafham, M. M., Bell, J. L., Linsell, L., Staplin, N., Emberson, J., Palfreeman, A., Raw, J., Elmahi, E., Prudon, B., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)32013-4 · Cited by 708
Metallodrugs are unique: opportunities and challenges of discovery and development
Anthony, E. J., Bolitho, E. M., Bridgewater, H. E., Carter, O. W. L., Donnelly, J. M., Imberti, C., Lant, E. C., Lermyte, F., Needham, R. J., Palau, M., et al. (2020) · Chemical Science · doi:10.1039/d0sc04082g · Cited by 727
Nadim, M. K., Forni, L. G., Mehta, R. L., Connor, M. J., Jr., Liu, K. D., Ostermann, M., Rimmele, T. R., Zarbock, A., Bell, S., Bihorac, A., et al. (2020) · Nature Reviews Nephrology · doi:10.1038/s41581-020-00356-5 · Cited by 701
Therapeutic strategies for COVID-19: progress and lessons learned
Li, G., Hilgenfeld, R., Whitley, R. J., & Clercq, E. D. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-023-00672-y · Cited by 714
Salvarani, C., Dolci, G., Massari, M., Merlo, D. F., Cavuto, S., Savoldi, L., Bruzzi, P., Boni, F., Braglia, L., Turrà, C., et al. (2020) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2020.6615 · Cited by 696
Evans, R. A., McAuley, H., Harrison, E. M., Shikotra, A., Singapuri, A., Sereno, M., Elneima, O., Docherty, A. B., Lone, N., Leavy, O. C., et al. (2021) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(21)00383-0 · Cited by 692
Effects of COVID-19 on the Nervous System
Iadecola, C., Anrather, J., & Kamel, H. (2020) · Cell · doi:10.1016/j.cell.2020.08.028 · Cited by 674
Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19
Dougan, M., Nirula, A., Azizad, M., Mocherla, B., Gottlieb, R. L., Chen, P., Hebert, C., Perry, R., Boscia, J., Heller, B., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2102685 · Cited by 663
Izcovich, A., Ragusa, M. A., Tortosa, F. G., Marzio, M. A. L., Agnoletti, C., Bengolea, A., Ceirano, A., Espinosa, F., Saavedra, E., Sanguine, V., et al. (2020) · PLoS ONE · doi:10.1371/journal.pone.0241955 · Cited by 676
Long COVID: post-acute sequelae of COVID-19 with a cardiovascular focus
Raman, B., Bluemke, D. A., Lüscher, T. F., & Neubauer, S. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac031 · Cited by 717
Artificial intelligence in COVID-19 drug repurposing
Zhou, Y., Wang, F., Tang, J., Nussinov, R., & Cheng, F. (2020) · The Lancet Digital Health · doi:10.1016/s2589-7500(20)30192-8 · Cited by 636
Wastnedge, E., Reynolds, R. M., van Boeckel, S. R., Stock, S. J., Denison, F. C., Maybin, J. A., & Critchley, H. (2020) · Physiological Reviews · doi:10.1152/physrev.00024.2020 · Cited by 698
Arnold, D., Hamilton, F., Milne, A., Morley, A. J., Viner, J., Attwood, M., Noel, A. R., Gunning, S., Hatrick, J., Hamilton, S., et al. (2020) · Thorax · doi:10.1136/thoraxjnl-2020-216086 · Cited by 645
INSPIRATION Investigators, Mazloomzadeh, S., Khaleghparast, S., Ghadrdoost, B., Mousavizadeh, M., Baay, M. R., Noohi, F., Sharifnia, H., Ahmadi, A., Tavan, S., et al. (2021) · JAMA · doi:10.1001/jama.2021.4152 · Cited by 638
Innate immunity: the first line of defense against SARS-CoV-2
Diamond, M., & Kanneganti, T. (2022) · Nature Immunology · doi:10.1038/s41590-021-01091-0 · Cited by 639
The signal pathways and treatment of cytokine storm in COVID-19
Yang, L., Xie, X., Tu, Z., Fu, J., Xu, D., & Zhou, Y. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00679-0 · Cited by 618
Immunity, endothelial injury and complement-induced coagulopathy in COVID-19
Perico, L., Benigni, A., Casiraghi, F., Ng, L. F. P., Rénia, L., & Remuzzi, G. (2020) · Nature Reviews Nephrology · doi:10.1038/s41581-020-00357-4 · Cited by 616
Rhino-Orbital Mucormycosis Associated With COVID-19
Mehta, S. A., & Pandey, A. (2020) · Cureus · doi:10.7759/cureus.10726 · Cited by 583
Uyeki, T. M., Hui, D. S. C., Zambon, M. C. F. A., Wentworth, D. E., & Monto, A. S. (2022) · The Lancet · doi:10.1016/s0140-6736(22)00982-5 · Cited by 596
Gupta, S., Wang, W., Hayek, S. S., Chan, L., Mathews, K. S., Melamed, M. L., Brenner, S. K., Leonberg-Yoo, A., Schenck, E. J., Radbel, J., et al. (2021) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2020.6252 · Cited by 535
SARS-CoV-2 infection triggers profibrotic macrophage responses and lung fibrosis
Wendisch, D., Dietrich, O., Mari, T., von Stillfried, S., Ibarra, I. L., Mittermaier, M., Mache, C., Chua, R. L., Knoll, R., Timm, S., et al. (2021) · Cell · doi:10.1016/j.cell.2021.11.033 · Cited by 528
Immunopathology of Hyperinflammation in COVID-19
Gustine, J. N., & Jones, D. (2021) · The American Journal of Pathology · doi:10.1016/j.ajpath.2020.08.009 · Cited by 516
Abaleke, E., Abbas, M. A., Abbasi, S., Abbott, A., Abdelaziz, A., Abdelbadiee, S., Abdelfattah, M., Abdul, B., Rasheed, A. A., Kadir, R. A., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00149-5 · Cited by 561
Henderson, L. A., Canna, S., Friedman, K. G., Gorelik, M., Lapidus, S., Bassiri, H., Behrens, E. M., Ferris, A. M., Kernan, K. F., Schulert, G. S., et al. (2020) · Arthritis & Rheumatology · doi:10.1002/art.41454 · Cited by 540
Inflammasome activation in infected macrophages drives COVID-19 pathology
Sefik, E., Qu, R., Junqueira, C., Kaffe, E., Mirza, H., Zhao, J., Brewer, J. R., Han, A., Steach, H. R., Israelow, B., et al. (2022) · Nature · doi:10.1038/s41586-022-04802-1 · Cited by 543
Schurink, B., Roos, E., Radonic, T., Barbé, E., Bouman, C. S. C., de Boer, H. H., de Bree, G. J., Bulle, E., Aronica, E., Florquin, S., et al. (2020) · The Lancet Microbe · doi:10.1016/s2666-5247(20)30144-0 · Cited by 517
Convalescent Plasma Antibody Levels and the Risk of Death from Covid-19
Joyner, M. J., Carter, R. E., Senefeld, J. W., Klassen, S. A., Mills, J. R., Johnson, P. W., Theel, E. S., Wiggins, C. C., Bruno, K. A., Klompas, A. M., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2031893 · Cited by 509
Organ-specific manifestations of COVID-19 infection
Gavriatopoulou, M., Korompoki, E., Fotiou, D., Ntanasis‐Stathopoulos, I., Ψαλτοπούλου, Θ., Kastritis, E., Terpos, E., & Dimopoulos, M. A. (2020) · Clinical and Experimental Medicine · doi:10.1007/s10238-020-00648-x · Cited by 501
Pathophysiology of COVID-19-associated acute kidney injury
Legrand, M. M., Bell, S., Forni, L. G., Joannidis, M., Koyner, J. L., Liu, K. D., & Cantaluppi, V. (2021) · Nature Reviews Nephrology · doi:10.1038/s41581-021-00452-0 · Cited by 527
Dequin, P., Heming, N., Meziani, F., Plantefève, G., Voiriot, G., Badie, J. C., François, B., Aubron, C., Ricard, J.-D., Ehrmann, S., et al. (2020) · JAMA · doi:10.1001/jama.2020.16761 · Cited by 511
Abani, O., Abbas, A. H., Abbas, F., Abbas, M. A., Abbasi, S., Abbass, H., Abbott, A., Abdallah, N., Abdelaziz, A., Abdelfattah, M., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00897-7 · Cited by 493
Drug repurposing approach to fight COVID-19
Singh, T. U., Parida, S., Lingaraju, M. C., Kesavan, M., Kumar, D., & Singh, R. K. (2020) · Pharmacological Reports · doi:10.1007/s43440-020-00155-6 · Cited by 490
Incidence of VTE and Bleeding Among Hospitalized Patients With Coronavirus Disease 2019
Jiménez, D., García‐Sánchez, A., Rali, P. M., Muriel, A., Bikdeli, B., Ruiz‐Artacho, P., Mao, R. L., Rodríguez, C., Hunt, B. J., & Monréal, M. (2020) · CHEST Journal · doi:10.1016/j.chest.2020.11.005 · Cited by 479
Global pandemics interconnected — obesity, impaired metabolic health and COVID-19
Stefan, N., Birkenfeld, A. L., & Schulze, M. B. (2021) · Nature Reviews Endocrinology · doi:10.1038/s41574-020-00462-1 · Cited by 452
Qadir, N., Sahetya, S. K., Munshi, L., Summers, C., Abrams, D. C., Beitler, J. R., Bellani, G., Brower, R. G., Burry, L. D., Chen, J., et al. (2023) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202311-2011st · Cited by 496
Coronavirus vaccine development: from SARS and MERS to COVID-19
Li, Y.-D., Chi, W.-Y., Su, J.-H., Ferrall, L., Hung, C., & Wu, T. ‐. (2020) · Journal of Biomedical Science · doi:10.1186/s12929-020-00695-2 · Cited by 486
Bravata, D. M., Perkins, A. J., Myers, L. J., Arling, G. W., Zhang, Y., Zillich, A. J., Reese, L. J., Dysangco, A. T., Agarwal, R., Myers, J. L., et al. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.34266 · Cited by 442
The Emergence of COVID-19 Associated Mucormycosis: Analysis of Cases From 18 Countries
Hoenigl, M., Seidel, D., Carvalho, A., Rudramurthy, S. M., Arastehfar, A. A., Gangneux, J., Nasir, N., Bonifaz, A., Araiza, J., Klimko, N., et al. (2021) · The Lancet Microbe · doi:10.1016/s2666-5247(21)00237-8 · Cited by 539
Applications of single-cell RNA sequencing in drug discovery and development
de Sande, B. V., Lee, J. S., Mutasa-Gottgens, E., Naughton, B. J., Bacon, W., Manning, J. R., Wang, Y., Pollard, J. R., Mendez, M., Hill, J., et al. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-023-00688-4 · Cited by 462
The first 12 months of COVID-19: a timeline of immunological insights
Carvalho, T., Krammer, F., & Iwasaki, A. (2021) · Nature reviews. Immunology · doi:10.1038/s41577-021-00522-1 · Cited by 483
Xu, S., Ilyas, I., & Weng, J. (2022) · Acta Pharmacologica Sinica · doi:10.1038/s41401-022-00998-0 · Cited by 483
Obesity as a multisystem disease: Trends in obesity rates and obesity‐related complications
Sarma, S., Sockalingam, S., & Dash, S. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14290 · Cited by 485
Specialized pro-resolving mediator network: an update on production and actions
Chiang, N., & Serhan, C. N. (2020) · Essays in Biochemistry · doi:10.1042/ebc20200018 · Cited by 455
The ‘cytokine storm’: molecular mechanisms and therapeutic prospects
Karki, R., & Kanneganti, T. (2021) · Trends in Immunology · doi:10.1016/j.it.2021.06.001 · Cited by 464
Evans, P. C., Rainger, G. E., Mason, J. C., Guzik, T. J., Osto, E., Stamataki, Z., Neil, D., Hoefer, I. E., Fragiadaki, M., Waltenberger, J. L., et al. (2020) · Cardiovascular Research · doi:10.1093/cvr/cvaa230 · Cited by 446
Monk, P., Marsden, R., Tear, V. J., Brookes, J. L., Batten, T. N., Mankowski, M., Gabbay, F. J., Davies, D. E., Holgate, S. T., Ho, L., et al. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(20)30511-7 · Cited by 441
Metadata
- Authors
- The RECOVERY Collaborative Group
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-02-25
- Volume
- 384
- Issue
- 8
- Pages
- 693-704
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7383595
- OpenAlex
- W3042270788
- Cited by
- 11,477
- References
- 43
- Citations by year
- 2026: 301 · 2025: 573 · 2024: 932 · 2023: 1534 · 2022: 2623 · 2021: 3849
- FWCI
- 316.80
- Type
- journal article
- Language
- en
- Open access
- green
- doi.org
- Licence
- Locations
- New England Journal of Medicine (publishedVersion)
- medRxiv (acceptedVersion, cc-by)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- DiRROS repository (University of Maribor) (publishedVersion, cc-by)
- Repository@Nottingham (University of Nottingham) (publishedVersion, other-oa)
- Edinburgh Napier Research Repository (Edinburgh Napier University) (publishedVersion)
- Explore Bristol Research (publishedVersion, cc-by)
- ePrints Soton (University of Southampton) (acceptedVersion)
- ORCA Online Research @Cardiff (Cardiff University) (acceptedVersion)
- St George's Online Research Archive (St George's University of London) (acceptedVersion)
- UEA Digital Repository (University of East Anglia) (acceptedVersion)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (acceptedVersion, cc-by-sa)
- Repository@Nottingham (University of Nottingham) (submittedVersion, cc-by)
- Spiral (Imperial College London) (submittedVersion)
- Sussex Research Online (University of Sussex) (submittedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Figshare (submittedVersion)
- Edinburgh Napier Research Repository (Edinburgh Napier University) (submittedVersion)
- University of Birmingham Research Portal (University of Birmingham) (submittedVersion, other-oa)
- Research Explorer (The University of Manchester) (submittedVersion)
- Edinburgh Research Explorer (University of Edinburgh) (submittedVersion, other-oa)
- Queen Mary Research Online (Queen Mary University of London) (submittedVersion)
- St Andrews Research Repository (St Andrews Research Repository) (submittedVersion)
- Apollo (University of Cambridge) (submittedVersion)
- Apollo
- Funders
- United Kingdom Research and Innovation (MC_PC_19056)
- National Institute for Health Research (MC_PC_19056)
- Topics
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Respiratory Support and Mechanisms
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Keywords
- dexamethasone, COVID-19 pandemic, glucocorticoids, 28-day mortality, invasive mechanical ventilation, oxygen therapy, respiratory support, lung injury, anti-inflammatory therapy, hospitalized patients, RECOVERY trial, usual care comparison, treatment effect heterogeneity
- MeSH terms
- COVID-19, COVID-19 Drug Treatment, Administration, Oral, Aged, Aged, 80 and over, Anti-Infective Agents, Dexamethasone, Drug Therapy, Combination, Female, Glucocorticoids, United Kingdom, Hospitalization, Humans, Injections, Intravenous, Length of Stay, Male, Oxygen Inhalation Therapy, Respiration, Artificial, Odds Ratio, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
